Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6354MR)

This product GTTS-WQ6354MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6354MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8963MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ1772MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ15196MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ11412MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ14860MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7442MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ5297MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ14615MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW